Classified in: Economy, health
Theme : Company acquisitions and mergers
ZUG, Switzerland, Feb. 22, 2024 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), one of the world's leading medical technology companies, today announced that it has made an offer to acquire VIMS. a France-based company specializing in the development and marketing of visualization systems for laparoscopy and arthroscopy procedures.
The combination of Zimmer Biomet's innovative solutions with VIMS technology will create a significant growth opportunity and provide a way to make its services available to more patients.
Zimmer Biomet already has an exclusive distribution agreement for arthroscopy imaging systems with VIMS in several European countries*.
According to French law, the signing of a binding agreement occurs once the consultation process of the company's Social and Economic Committee has been completed. The proposed acquisition is expected to close in the first half of 2024, subject to customary closing conditions, including, but not limited to, receipt of regulatory approvals.
*Spain, Portugal, Italy, Czech Republic, Slovakia, Netherlands and Switzerland
About Zimmer Biomet
Zimmer Biomet is a major player in medical technology with a comprehensive range to improve patient mobility and quality of life. We support the patient experience through our innovative products as well as our digital technology and integrated robotics solutions including data analytics and the use of artificial intelligence.
With more than 90 years of presence and expertise, Zimmer Biomet is committed to providing patients and its partners with the highest quality solutions. Our heritage continues to come alive today through our progressive culture of evolution and innovation.
For more information about our product portfolio, operations in over 25 countries and sales in over 100 countries, or to join our team, visit www.zimmerbiomet.com or follow us on LinkedIn at www.linkedin.com/company/zimmerbiomet or on X /Twitter via the link www.twitter.com/zimmerbiomet.
Information about forward-looking statements
This press release contains information that contains or is based on forward-looking statements within the meaning of the United States Securities Act of 1995. Forward-looking statements include, but are not limited to, statements regarding Zimmer Biomet's prospects, forecasts, expectations, and product and service offerings. These statements are based on management's current beliefs and expectations and are subject to significant risks, contingencies and changes in circumstances that could cause results to differ materially from original expectations. A list and description of some of these risks and hazards can be found in Zimmer Biomet's periodic reports filed with the United States federal government's independent agency, the Securities and Exchange Commission (SEC). These factors should not be considered exhaustive and should be read in conjunction with other cautionary statements contained in Zimmer Biomet's filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this press release are cautioned not to place undue reliance on these forward-looking statements as there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement applies to all forward-looking statements contained in this press release.
These press releases might also interest you
|
Press release sent on February 22, 2024 at 2:00 a.m. and distributed by:
